Adicet bio to participate in a fireside chat at the 2023 guggenheim oncology conference

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced that chen schor, president and chief executive officer, will participate in a fireside chat at the 2023 guggenheim oncology conference being held from february 8-9, 2023. details of the event are as follows: date: thursday, february 9, 2023 time: 2:10 p.m. et the live audio webcast can be accessed on the investors section of adicet bio’s website at http://www.adicetbio.com. an archived replay will be available for 30 days following the presentation. about adicet bio, inc. adicet bio, inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer. adicet is advancing a pipeline of “off-the-shelf” gamma delta t cells, engineered with chimeric antigen receptors (cars) and adaptors (cads), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. for more information, please visit our website at https://www.adicetbio.com.
ACET Ratings Summary
ACET Quant Ranking